Tumour heterogeneity of mucosal melanomas during treatment with imatinib

British Journal of Dermatology

Volumn 165, Issue 2, 2011, Pages 419-424

  Schoenewolf, N L ^a   Urosevic Maiwald, M ^a   Dummer, R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DACARBAZINE; IMATINIB; TEMOZOLOMIDE;

ADULT; AGED; ANAMNESIS; ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CELL CULTURE; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; LYMPHADENECTOMY; MELANOMA; MELANOMA CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE C KIT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; TREATMENT RESPONSE; TUMOR GROWTH; VULVECTOMY;

AGED; ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; FATAL OUTCOME; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECTAL NEOPLASMS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VULVAR NEOPLASMS;

EID: 79960644237     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10376.x     Document Type: Article

References (32)

1. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47. (Pubitemid 41653105)
2. Bastian BC, LeBoit PE, Hamm H, et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998; 58: 2170-5. (Pubitemid 28232904)
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54. (Pubitemid 34716871)
4. Cohen C, Zavala-Pompa A, Sequeira JH, et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 2002; 8: 3728-33. (Pubitemid 35424762)
5. Gray-Schopfer V, Wellbrock C, Marais R,. Melanoma biology and new targeted therapy. Nature 2007; 445: 851-7.
6. Curtin JA, Busam K, Pinkel D, Bastian BC,. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-6. (Pubitemid 46630793)
7. Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007; 121: 257-64. (Pubitemid 46917693)
8. Ashida A, Takata M, Murata H, et al. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 2009; 124: 862-8.
9. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14: 6821-8.
10. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26: 2046-51.
11. Holden JA, Willmore-Payne C, Layfield LJ,. Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology. Exp Mol Pathol 2008; 85: 68-75.
12. Jiang X, Zhou J, Yuen NK, et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008; 14: 7726-32.
13. Lutzky J, Bauer J, Bastian BC,. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008; 21: 492-3. (Pubitemid 351990966)
14. McLean SR, Gana-Weisz M, Hartzoulakis B, et al. Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Mol Cancer Ther 2005; 4: 2008-15. (Pubitemid 43056984)
15. Quintas-Cardama A, Lazar AJ, Woodman SE, et al. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008; 5: 737-40.
16. Rivera RS, Nagatsuka H, Gunduz M, et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008; 452: 27-32.
17. Satzger I, Küttler U, Völker B, et al. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy-case report and review of the literature. Dermatology 2010; 220: 77-81.
18. Satzger I, Schaefer T, Kuettler U, et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 2008; 99: 2065-9.
19. Terheyden P, Houben R, Pajouh P, et al. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. J Invest Dermatol 2010; 130: 314-16.
20. Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ,. BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 2006; 37: 520-7.
21. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ,. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 2005; 36: 486-93. (Pubitemid 40776001)
22. Carvajal RD, Chapman PB, Wolchok JD, et al. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol 2009; 27 (Suppl.): Abstract 9001.
23. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008; 99: 734-40.
24. Kluger HM, Dudek A, McCann C, et al. A phase II trial of dasatinib in advanced melanoma. J Clin Oncol 2009; 27 (Suppl.):Abstract 9010.
25. Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009; 8: 2079-85.
26. Yamaguchi M, Harada K, Ando N, et al. Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb. Clin Exp Dermatol 2011; 36: 174-7.
27. Zhu Y, Si L, Kong Y, et al. Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma. J Clin Oncol 2009; 27 (Suppl.):Abstract e20017.
28. Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009; 106: 20411-16.
29. Tarn C, Merkel E, Canutescu AA, et al. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res 2005; 11: 3668-77. (Pubitemid 40685583)
30. Handolias D, Hamilton AL, Salemi R, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 2010; 102: 1219-23.
31. Woodman SE, Davies MA,. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 2010; 80: 568-74.
32. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.